TCL Archive Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months September 27, 2013
TCL Archive Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products. July 9, 2004
TCL Archive Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response December 28, 2012